Pennsylvania, November 17, 2026
Uniquity Bio, a clinical-stage biopharmaceutical company focused on immunology and inflammatory diseases and backed by Blackstone Life Sciences, has announced positive topline results from its Phase 2 ALAMERE clinical trial evaluating solrikitug in adults with eosinophilic esophagitis (EoE). The investigational monoclonal antibody demonstrated statistically significant and clinically meaningful improvements across the trial’s co-primary endpoints at week 24, including histologic remission and difficulty swallowing. The findings support the potential of solrikitug as a differentiated biological therapy for EoE, a chronic inflammatory condition with limited treatment options. Following the successful Phase 2 outcomes, Uniquity Bio plans to initiate a pivotal Phase 3 clinical trial in the first quarter of 2027.
Solrikitug Demonstrates Significant Phase 2 Clinical Benefits
The randomized, double-blind, placebo-controlled ALAMERE Phase 2 study evaluated three doses of solrikitug: 125 mg, 250 mg and 500 mg, administered through subcutaneous injections every four weeks. At week 24, treatment achieved placebo-corrected histologic remission rates of 69%–76% across all doses tested, with statistically significant results (p<0.001). Histologic remission was assessed by measuring eosinophil levels in esophageal tissue, providing an important indication of improvement in underlying inflammation. Solrikitug also demonstrated reductions in the frequency and severity of dysphagia symptoms, achieving placebo-corrected improvements of 8.8–12.6 points on the Dysphagia Symptom Questionnaire (DSQ). The results were statistically significant across the studied dose groups. Additional improvements were observed in secondary endpoints, including the Eosinophilic Esophagitis Endoscopic Reference Score (EREFS), the EoE Histology Scoring System (EoE-HSS) and the number of dysphagia-free days. According to Uniquity Bio, the investigational therapy was well tolerated and demonstrated a favorable safety profile during the study.
TSLP-Targeting Monoclonal Antibody Advances EoE Treatment
Solrikitug is a highly potent monoclonal antibody designed to target thymic stromal lymphopoietin (TSLP), an important cytokine involved in inflammatory and allergic immune responses. By inhibiting TSLP activity, the investigational biologic aims to interfere with upstream inflammatory pathways that contribute to eosinophilic esophagitis. EoE is a chronic immune-mediated inflammatory disease affecting the esophagus and is commonly associated with difficulty swallowing, food impaction, chest discomfort, vomiting and abdominal pain. Persistent inflammation may lead to complications such as esophageal fibrosis and strictures. The condition affects an estimated 470,000 people in the United States, according to the company announcement, highlighting the need for additional effective treatment options. The ALAMERE results indicate that targeting TSLP may provide meaningful benefits across both tissue-level inflammation and patient-reported swallowing symptoms. Uniquity Bio believes the findings support the potential for a best-in-class therapeutic profile, including a possible extended dosing interval beyond four weeks. However, the optimal dosing schedule and durability of response will require further clinical evaluation.
Uniquity Bio Plans Pivotal Phase 3 Trial in 2027
Following the positive topline findings, Uniquity Bio plans to begin its pivotal Phase 3 trial in Q1 2027. The company has reported positive discussions with the U.S. Food and Drug Administration (FDA), indicating that one pivotal Phase 3 study, together with the ALAMERE Phase 2 study as confirmatory evidence, could potentially support a future Biologics License Application (BLA). The company is continuing to monitor participants through week 52 to assess the durability of treatment response and longer-term safety. Full clinical findings are expected to be presented at a future scientific medical congress. Commenting on the results, Will Kane, Chief Executive Officer of Uniquity Bio, highlighted the potential of solrikitug to improve the daily experiences of people living with EoE. Clinical investigator Dr. Evan Dellon, Professor of Medicine at the University of North Carolina School of Medicine, also emphasized the consistent improvements observed across symptom measurements, endoscopic assessments and histologic disease activity.
Source: Uniquity Bio press release



